Champions Oncology (CSBR) Change in Account Payables (2010 - 2026)
Champions Oncology (CSBR) recorded quarterly Change in Account Payables of -$437000.0 in Q1 2026, down 133.33% quarter-over-quarter from $1.3 million in Q4 2025, and down 132.45% on a YoY basis from $1.3 million in Q1 2025.
Champions Oncology (CSBR) Change in Account Payables (2010 - 2026) Analysis & Trends
Champions Oncology's Change in Account Payables history runs 17 years deep, the most recent figure standing at -$437000.0 for Q1 2026.
- In Q1 2026, Change in Account Payables fell 132.45% year-over-year to -$437000.0; the TTM figure through Jan 2026 stood at $671000.0 (up 829.35% YoY), while the FY2025 annual figure was -$1.7 million, down 476.13% from the prior year.
- Change in Account Payables was -$437000.0 for Q1 2026 at Champions Oncology, down from $1.3 million in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $2.1 million in Q4 2022 to a low of -$1.2 million in Q4 2023.
- Historically, Change in Account Payables has averaged $113764.7 across 5 years, with a median of -$188000.0 in 2025.
- Biggest YoY gain for Change in Account Payables was 1443.28% in 2022; the steepest drop was 635.57% in 2022.
- A 5-year view of Change in Account Payables shows it stood at $2.1 million in 2022, then slumped by 159.19% to -$1.2 million in 2023, then soared by 68.79% to -$382000.0 in 2024, then surged by 443.19% to $1.3 million in 2025, then slumped by 133.33% to -$437000.0 in 2026.
- The last three Change in Account Payables figures came in at -$437000.0 (Q1 2026), $1.3 million (Q4 2025), and $411000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -3.26 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 35.60 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -9.42 Mn |
| 10 | Champions Oncology | 78.46 Mn | 71.46 Mn | 13.89 Mn | -437,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 31, 2026 | -437,000.00 |
| Jan 31, 2026 | -437,000.00 |
| Oct 31, 2025 | 1.31 Mn |
| Oct 31, 2025 | 1.31 Mn |
| Jul 31, 2025 | 411,000.00 |
| Jul 31, 2025 | 411,000.00 |
| Apr 30, 2025 | -614,000.00 |
| Apr 30, 2025 | -614,000.00 |
| Jan 31, 2025 | -188,000.00 |
| Jan 31, 2025 | -188,000.00 |
| Oct 31, 2024 | -382,000.00 |
| Oct 31, 2024 | -382,000.00 |
| Jul 31, 2024 | -565,000.00 |
| Jul 31, 2024 | -565,000.00 |
| Apr 30, 2024 | 1.04 Mn |
| Apr 30, 2024 | 1.04 Mn |
| Jan 31, 2024 | 222,000.00 |
| Jan 31, 2024 | 222,000.00 |
| Oct 31, 2023 | -1.22 Mn |
| Oct 31, 2023 | -1.22 Mn |